Janssen seeks to halt generic schizophrenia drug

22-02-2022

Janssen seeks to halt generic schizophrenia drug

Michael Vi / Shutterstock.com

Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate). 


Janssen, Johnson & Johnson, Intas Pharmaceuticals, Accord Healthcare, generics, ANDA, patent infringement, blockbuster drug

LSIPR